Travere Therapeutics Announces Confirmatory Data from the Phase 3 Protect Study of Filspari Demonstrating Long-Term Kidney Function Preservation in Iga Nephropathy; Narrowly Missing Egfr Total Slope Endpoint Versus Active Control, Irbesartan

Travere Therapeutics, Inc. announced topline two-year confirmatory secondary endpoint results from the Company?s pivotal head-to-head Phase 3 PROTECT Study of FILSPARI® in IgA nephropathy versus...

Related Keywords

,European Medicines Agency ,Committee For Medicinal Products Human Use ,Travere Therapeutics Inc ,Travere Therapeutics ,New Drug Application ,Conditional Marketing Authorization ,Medicinal Products ,Human Use ,Markets ,